CME Information

Learning Objectives:

At the conclusion of the program, participants will be better able to:

• Interpret principles of anatomy and pathophysiology for a variety of clinical conditions in order to assess the need for botulinum neurotoxin treatment
• Perform comprehensive and individualized patient assessment in order to identify appropriate patients for neurotoxin therapy and determine realistic treatment goals
• Understand the different toxin formulations, in order to a administer a specific therapeutic regimen appropriate for each individual patient
• Demonstrate procedures and techniques for neurotoxin injections including the use of localization and guidance modalities, in order to assure optimal product placement and therapeutic outcomes

Target Audience:

The preceptorship program is designed for clinicians in the fields of neurology, physical medicine and rehabilitation, as well as other specialties who wish improve and/or expand their knowledge and skills in the management of patients with clinical conditions for which botulinum neurotoxin (BoNT) is an evidence-based treatment option.

Faculty/Mentors:

Katharine Alter, MD
Medical Director, FABS, Senior Clinician NIH
NIH, NIDS
University Park, Maryland

Laxman Bahroo, DO
Assistant Professor of Neurology
Medstar Georgetown University Hospital
McLean, Virginia

David Charles, MD
Professor and Vice-Chair of Neurology
Vanderbilt University Medical Center
Nashville, Tennessee

Cindy Ivanhoe, MD
Clinical Professor, Physical Medicine and Rehabilitation
University of Texas McGovern School of Medicine and Baylor College of Medicine
Houston, Texas

David Simpson, MD
Professor of Neurology; Director, Clinical Neurophysiology Labs and Neuromuscular Division
Icahn School of Medicine at Mount Sinai
New York, New York

Conflict of Interest Statement

The Conflict of Interest Disclosure Policy of Albert Einstein College of Medicine and Montefiore Medical Center requires that faculty participating in any CME activity disclose to the audience any relationship(s) with a pharmaceutical, product or device company. Any presenter who has disclosed relationships that prove to create a conflict of interest, with regard to their contribution to the activity, will not be permitted to present.

Albert Einstein College of Medicine also requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product, or device not yet approved for use in the United States.

Planning Committee Disclosures: 

Katharine Alter, MD

Laxman Bahroo, DO

David Charles, MD

Cindy Ivanhoe, MD

David Simpson, MD

CME Program Reviewer

Victor B. Hatcher, PhD** has indicated no conflict of interest.

This CME activity discusses the off-label use of botulinum neurotoxin (BoNT)

Americans With Disabilities Act:

Albert Einstein College of Medicine and International Neurotoxin Association (INA). fully intends to comply with the legal requirements of the American with Disabilities Act. If any participant of this activity is in need of special accommodations, please contact INA at least two weeks prior to the activity at preceptorship@neurotoxins.org

Sponsorship Statement:

This activity is jointly provided by Albert Einstein College of Medicine-Montefiore Medical Center and the International Neurotoxin Association (INA).

Supported by an educational grant and in-kind contribution of disposable and biological supplies from AbbVie and an educational grant and in-kind contribution of product from Merz.

ACCME Accreditation Statement:

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Albert Einstein College of Medicine and the International Neurotoxin Association (INA). Albert Einstein College of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation Statement:

Albert Einstein College of Medicine designates this live activity for a maximum of 4.0 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in this activity.